PharmaVentures Establishes an Office in Seoul to Enhance Access for South Korean Biotechs

PharmaVentures announces its new office in South Korea as part of its continued strategic expansion. Headquartered in London, UK, PharmaVentures has been assisting Korean biopharma companies for more than 5 years on various transaction and strategy projects. JungHyun Eom is now based in Seoul, South Korea, to support current and prospective clients in the emerging Korean biotech sector.

JungHyun Eom, Associate, said, “We are excited to be out in Korea communicating with these innovators closely. We will continue bringing value to the Korean bio industry and serving as the bridge between the innovation in Asia and its commercialisation to the rest of the world.”

Fintan Walton, Founder and CEO of PharmaVentures, said “PharmaVentures’ specialist knowledge and experience of the Korean emerging biopharmaceutical sector sets us apart from other transactions advisory firms, even more so now that we have JungHyun Eom based in Korea full time. By establishing ourselves on the ground, we will strengthen our relationships with the Korean bio industry and the wider APAC region.”

South Korea is recognised globally as a leading nation for innovation. Western pharma companies are increasingly turning their attention to the rapidly expanding biotech sector there. PharmaVentures has successfully acted as the bridge between Western pharma and Korean biotech innovators on over 40 transactional projects. The company has 4 bilingual Korean speakers with strong scientific/technical background. Leveraging over 30 years of experience in the global biopharma deal making scene, PharmaVentures has helped Korean companies to meet their strategic objectives by connecting the Korean and Western Biopharma industries through licensing and M&A deals.

Over the past 5 years, PharmaVentures has been collaborating with several Korean government institutions such as SEOUL BIOHUB, Korea Health Industry Development Institute (KHIDI) and Korea Drug Development Fund (KDDF) to provide educational and thought leadership activities, working towards globalising the Korean biopharma industry. PharmaVentures also has good relationships with Korean financial groups. The company signed a Memorandum of Understanding (MOU) with Shinhan Investment Corp to collaborate closely to provide a broader range of capabilities and services to both Korean biotech companies and global biopharma companies looking at Korean biotech opportunities.

PharmaVentures is taking this step during an historic year where we are a proud sponsor of the UK Government led celebrations of the 140^th anniversary of UK-Korea relations.